COPD: An inflammatory disease of the airways?;COPD: Eine entzündliche erkrankung der atemwege?

Pneumologie

Volumn 58, Issue 5, 2004, Pages 320-324

  Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; E1A PROTEIN; GLUCOCORTICOID; INTERLEUKIN 8; ISOPROSTANE; NITRIC OXIDE; STEROID; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; FORCED EXPIRATION; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; STEROID THERAPY; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 2542593110     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818401     Document Type: Review

References (49)

1. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276
2. Worth H, Buhl R, Cegla U et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 2002; 56: 704-738
3. Ferguson GT, Enright PL, Buist AS et al. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117: 1146-1161
4. Halbert RJ, Isonaka S, George D et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-1692
5. Viegi G, Pedreschi M, Pistelli F et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117: 339S-345S
6. Schermer TR, Jacobs JE, Chavannes NH et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003; 58: 861-866
7. Fletcher C, Peto R, Tinker C et al. The natural history of chronic bronchitis and emphysema. Oxford University Press, 1976
8. Pinto-Plata VM, Cote C, Cabral H et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33
9. Nishimura K, Izumi T, Tsukino M et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440
10. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565
11. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117: 42S-47S
12. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777
13. O'Donnell DE, Flüge T, Gerken F et al. Effects of Tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; in press
14. Taube C, Lehnigk B, Paasch K et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 216-220
15. Taube C, Kanniess F, Gronke L et al. Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma. Respir Med 2003; 97: 568-577
16. Saetta M, Turato G, Maestrelli P et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309
17. Turato G, Zuin R, Miniati M et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110
18. Retamales I, Elliott WM, Meshi B et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473
19. Agusti A, MacNee W, Donaldson K et al. Hypothesis: Does COPD have an autoimmune component? Thorax 2003; 58: 832-834
20. Holz O, Zühlke I, Jaksztat E et al. Lung fibroblasts from patients with emphysema show a reduced proliferation rate in culture. Eur Respir J 2004; submitted
21. Kips JC, Peleman RA, Pauwels RA. Methods of examining induced sputum: do differences matter? Eur Respir J 1998; 11: 529-533
22. Tsoumakidou M, Tzanakis N, Siafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir Med 2003; 97: 863-871
23. Taube C, Holz O, Mücke M et al. Airway Response to Inhaled Hypertonic Saline in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001; 164: 1810-1815
24. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-453
25. Richter K, Holz O, Jorres RA et al. Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 697-701
26. Jayaram L, Parameswaran K, Sears MR et al. Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 2000; 16: 150-158
27. Hargreave FE, Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S53-S57
28. Kelly MM, Keatings V, Leigh R et al. Analysis of fluid-phase mediators. Eur Respir J Suppl 2002; 37: 24s-39s
29. Kharitonov SA, Robbins RA, Yates D et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152: 609-612
30. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357
31. Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease. J Allergy Clin Immunol 2002; 110: 28-34
32. Schleiss MB, Holz O, Behnke M et al. The concentration of hydrogen peroxide in exhaled air depends on expiratory flow rate. Eur Respir J 2000; 16: 1115-1118
33. Rahman I. Reproducibility of oxidative stress biomarkers in breath condensate: are they reliable? Eur Respir J 2004; 23: 183-184
34. Magnussen H, Richter K, Taube C. Are chronic obstructive pulmonary disease (COPD) and asthma different diseases? Clin Exp Allergy 1998; 28 Suppl 5: 187-194
35. Decramer M, de B V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 1958-1964
36. Singh JM, Palda VA, Stanbrook MB et al. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med 2002; 162: 2527-2536
37. Loppow D, Schleiss MB, Kanniess F et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001; 95: 115-121
38. Culpitt SV, Maziak W, Loukidis S et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639
39. Niewoehner DE, Erbland ML, Deupree RH et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947
40. Sutherland ER, Allmers H, Ayas NT et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937-941
41. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003; 138: 969-973
42. Sin DD, McAlister FA, Man SF et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290: 2301-2312
43. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003; 21: 260-266
44. Fan VS, Bryson CL, Curtis JR et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003; 168: 1488-1494
45. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53
46. Rabe KF. Combination therapy for chronic obstructive pulmonary disease: one size fits all? Eur Respir J 2003; 22: 874-875
47. Nannini L, Lasserson T, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; 4: CD003794
48. Calverley PM, Burge PS, Spencer S et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664
49. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-259